146 related articles for article (PubMed ID: 36701329)
1. Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)-Study protocol.
Okunade KS; Badmos KB; Okoro AC; Ademuyiwa IY; Oshodi YA; Adejimi AA; Awolola NA; Ozonu O; Adelabu H; Olorunfemi G; Akanmu AS; Banjo AA; Anorlu RI; Berek JS
PLoS One; 2023; 18(1):e0278077. PubMed ID: 36701329
[TBL] [Abstract][Full Text] [Related]
2. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study.
Kelly HA; Chikandiwa A; Sawadogo B; Gilham C; Michelow P; Lompo OG; Omar T; Zan S; Magooa P; Segondy M; Nagot N; Meda N; Delany-Moretlwe S; Mayaud P;
PLoS Med; 2021 Mar; 18(3):e1003528. PubMed ID: 33661957
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China.
Zhang SK; Jia MM; Zhao DM; Wu ZN; Guo Z; Liu YL; Guo PP; Chen Q; Cao XQ; Liu SZ; Chen W; Sun XB
Cancer Epidemiol; 2019 Apr; 59():123-128. PubMed ID: 30739069
[TBL] [Abstract][Full Text] [Related]
6. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
[TBL] [Abstract][Full Text] [Related]
7. p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening.
Magkana M; Mentzelopoulou P; Magkana E; Pampanos A; Vrachnis N; Kalafati E; Daskalakis G; Domali E; Thomakos N; Rodolakis A; Anagnou NP; Pappa KI
Anticancer Res; 2022 May; 42(5):2599-2606. PubMed ID: 35489732
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
Yu LL; Chen W; Lei XQ; Qin Y; Wu ZN; Pan QJ; Zhang X; Chang BF; Zhang SK; Guo HQ; Qiao YL
Oncotarget; 2016 Apr; 7(16):21181-9. PubMed ID: 27029033
[TBL] [Abstract][Full Text] [Related]
9. Triage of HPV positivity in a high HIV prevalence setting: A prospective cohort study comparing visual triage methods and HPV genotype restriction in Botswana.
Luckett R; Ramogola-Masire D; Gompers A; Moraka N; Moyo S; Sedabadi L; Tawe L; Kashamba T; Gaborone K; Mathoma A; Noubary F; Kula M; Grover S; Dreyer G; Botha MH; Makhema J; Shapiro R; Hacker MR
Int J Gynaecol Obstet; 2024 May; 165(2):507-518. PubMed ID: 37950533
[TBL] [Abstract][Full Text] [Related]
10. Utility of p16, Ki-67, and HPV test in diagnosis of cervical intraepithelial neoplasia and atrophy in women older than 50 years with 3- to 7-year follow-up.
Jackson JA; Kapur U; Erşahin Ç
Int J Surg Pathol; 2012 Apr; 20(2):146-53. PubMed ID: 22104735
[TBL] [Abstract][Full Text] [Related]
11. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
13. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
Tay TKY; Lim KL; Hilmy MH; Thike AA; Goh ST; Song LH; Hwang JSG; Mantoo S
Malays J Pathol; 2017 Dec; 39(3):257-265. PubMed ID: 29279588
[TBL] [Abstract][Full Text] [Related]
15. Good performance of p16/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN/VAIN in a prospective, cross-sectional study.
Liu W; Gong J; Xu H; Zhang D; Xia N; Li H; Song K; Lv T; Chen Y; Diao Y; Jao J; Dai S; Zhao P; Yao Q
Diagn Cytopathol; 2020 Jul; 48(7):635-644. PubMed ID: 32275355
[TBL] [Abstract][Full Text] [Related]
16. P16/Ki-67 Dual Staining in Positive Human Papillomavirus DNA Testing for Predictive Diagnosis of Abnormal Cervical Lesions in Northeastern Thai Women.
Aromseree S; Wongjumpa W; Ekalaksananan T; Temtanakitpaisan A; Kleebkaow P; Srisathaporn S; Tongchai P; Pientong C
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3405-3411. PubMed ID: 36308365
[TBL] [Abstract][Full Text] [Related]
17. [Clinical value of p16
Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
[No Abstract] [Full Text] [Related]
18. Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study.
Wu TJ; Smith-McCune K; Reuschenbach M; von Knebel Doeberitz M; Maloba M; Huchko MJ
BMJ Open; 2016 Sep; 6(9):e012547. PubMed ID: 27625065
[TBL] [Abstract][Full Text] [Related]
19. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
Uijterwaal MH; Witte BI; Van Kemenade FJ; Rijkaart D; Ridder R; Berkhof J; Balfoort-van der Meij GA; Bleeker MC; Snijders PJ; Meijer CJ
Br J Cancer; 2014 Mar; 110(6):1579-86. PubMed ID: 24518601
[TBL] [Abstract][Full Text] [Related]
20. [Clinical value of p16/Ki-67 immunocytochemical dual staining in cervical cancer screening].
Wang HR; Liao GD; Chen W; Qiao YL; Jiang Y
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):636-640. PubMed ID: 28835090
[No Abstract] [Full Text] [Related]
[Next] [New Search]
